They concluded that SUSD2 acts as a RB tumor suppressor, and the miR-141-3p/SUSD2 axis could regulate both retinoblastoma development and angiogenesis, making it a new target for RB treatment (Liu and Wen, 2022). The gene discussed is SUSD2; the disease is neoplasm.